Who is sponsoring NCT00022373?

NCT00022373 is sponsored by National Cancer Institute (NCI).

What condition does NCT00022373 study?

NCT00022373 studies Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity.

What drugs are being tested in NCT00022373?

Interventions: iseganan HCl oral solution, management of therapy complications.

What is the status of NCT00022373?

NCT00022373 is currently UNKNOWN.

Last reviewed 2014-10-14 · How we verify

A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy

NCT00022373 Phase 3 UNKNOWN

RATIONALE: Iseganan hydrochloride may be effective in preventing or lessening oral mucositis in patients who are receiving radiation therapy for head and neck cancer. It is not yet known if iseganan hydrochloride is effective in preventing oral mucositis. PURPOSE: Randomized phase III trial to determine the effectiveness of iseganan hydrochloride in preventing oral mucositis in patients who are receiving radiation therapy for head and neck cancer.

Details

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 3
Status	UNKNOWN
Start date	2000-12

Conditions

Head and Neck Cancer
Oral Complications of Radiation Therapy
Radiation Toxicity

Interventions

iseganan HCl oral solution
management of therapy complications

Countries

United States